Synthetic Biology Key Players and their Developments
The synthetic biology market was estimated at US$ 16.39 billion in 2023 and is projected to grow to US$ 191.48 billion by 2034, rising at a compound annual growth rate (CAGR) of 25.04% from 2024 to 2034.
Top Companies in the Synthetic Biology Market
- Agilent Technologies
- Codexis
- CHAIN Biotech
- Eurofins Scientific
- GenScript
- Mammoth Biosciences
- Novozymes
- Pearl Bio
- Poseida Therapeutics
- Precigen
- Thermo Fisher Scientific
- Twist Bioscience
Latest Announcements by Industry Leaders
Dr. Avencia Sánchez-Mejias, CEO of Integra Therapeutics, revealed at a conference its new gene writing technology, FICAT, to contribute to the prevention and treatment of genetic diseases and cancer. She commented that the synthetic biology market is growing because it has demonstrated its revolutionary capacity to transform the development and production of therapies, vaccines, and diagnostics.
Recent Developments in the Synthetic Biology Market
- In November 2024, Asymchem’s Center of Synthetic Biology Technology developed an artificial intelligence platform, STAR (Sequence Recommendation via Artificial Intelligence), to address key challenges in protein design.
- In March 2024, Strand Therapeutics developed a class of mRNA molecules to express immune signals directly from a tumor, triggering the immune system to attack and kill the tumor cells directly.
If you have any questions, please feel free to contact us at
